Relationship between pharmaceutical pricing strategies with price, availability, and affordability of cardiovascular disease medicines: Surveys in Qatar and Lebanon
MetadataShow full item record
Background: Cardiovascular diseases are the leading cause of death in Lebanon and Qatar. When lifestyle modifications prove insufficient, medication becomes a cornerstone in controlling such diseases and saving lives. Price, availability, and affordability hinder the equitable access to medicines. The study aimed to assess prices, availability, and affordability of essential cardiovascular disease medicines in relation to pricing strategies in Qatar and Lebanon. Methods: A cross-sectional survey using a variant of the World Health Organization and Health Action International (WHO/HAI) methodology as outlined in "Measuring medicine prices, availability, affordability and price components" (2008), second edition, was adopted. Prices and availability of 27 cardiovascular medicines were collected from public and private dispensing outlets. For international comparison, prices were adjusted to purchasing power parity. Data was analyzed across multiple sectors, within and across countries. Results: A total of 15 public and private outlets were surveyed in each country. Prices were more uniform in Qatar than in Lebanon. In the public sector, medicines were free-of-charge in Lebanon and priced lower than the international reference prices in Qatar. The ratio of medicine unit price to international reference price in the private sectors surveyed are significantly higher than the acceptable threshold of 4. This ratio of originator brands and lowest priced generics in Qatar were up to two and five times those in Lebanon, respectively, even after adjusting for purchasing power parity. However, prices of lowest priced generics in the private sector were at least 35% cheaper in Qatar and 65% cheaper in Lebanon than their comparative originator brands. Medicines were more available in the private sector in Lebanon than in Qatar, but only the originator brand availability in the public sector in Qatar exceeded the WHO target of more than 80%. While affordable in the public sector in Qatar, four out of thirteen medicines exceeded the threshold in all private sectors covered. Hence, only the public sector in Qatar had a satisfying level of availability and affordability. Conclusions: Except for the Qatari public sector, medicine prices, availability, and affordability are falling short from targets. Key policy decisions should be implemented to improve access to medicines. - 2019 The Author(s).
- Pharmacy Research [279 items ]
Showing items related by title, author, creator and subject.
|Patients' lived experiences with antineoplastic medicines for the management of malignant solid tumours: A systematic review. ||Brincat, Alison; Bonanno, Patricia Vella; Stewart, Derek; Weidmann, Anita E||2020||Elsevier||Article|
|WHO Model List Of Essential Medicines and countries Health response during Embargo ||Alhajri, Mohd||2018||Presentation|
|Medicines Pricing Policy and Strategies in Developing Countries: A Review ||Abdel Rida N.; Ibrahim M.I.M.||2018||Elsevier Inc.||Book chapter|